Phase 1B Study of PTC299 in Relapsed/Refractory Acute Leukemias
Phase of Trial: Phase I
Latest Information Update: 17 Jan 2020
Price : $35 *
At a glance
- Drugs PTC 299 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors PTC Therapeutics
- 13 Jan 2020 Planned number of patients changed from 18 to 36.
- 27 Mar 2019 Planned number of patients changed from 36 to 18.
- 28 Feb 2019 According to a PTC Therapeutics media release, this study is expected to fully enroll by the end of 2019.